Precision Oncology Clinical Trials: How to Use Biomarker Reports to Find Options You Can Verify
After receiving a genetic or other biomarker report, first discuss with your oncologist what the next treatment needs to address. Then use the full report to search for studies, confirm with each hospital whether the study arm is open and whether it accepts your test results, and ask the research team to assess the other eligibility requirements. Before traveling, clarify screening timelines, costs, and care arrangements if you cannot enroll.
This guide is for patients and families considering travel to mainland China to participate in cancer research. Your care team will assess your specific treatment options.
Key points
- An “actionable” finding or a drug name in a report does not mean treatment will work or that a trial will accept you. First check the specific alteration, cancer type, sample, and testing method.
- A registration number helps you find a study. Registration, or a “recruiting” status for the overall study, does not prove that your chosen hospital and study arm are recruiting. Rely on the research team’s latest response about the specific site and cohort.
- Do not stop medication or delay treatment on your own while waiting for a match. Ask your treating doctor and the research team to discuss how long you can safely wait and what happens if you do not pass screening.
- If you have severe difficulty breathing, sudden confusion or loss of consciousness, chest pain, or heavy bleeding in mainland China, call 120 immediately or go to the nearest emergency department. Get emergency care first, then notify the research team.
First decide whether to look for routine treatment or research
Ask your doctor to explain, based on your pathology, previous treatment, and the purpose of this test, which routine treatments are available, which options are still being studied, and whether waiting for results could affect the treatment you need now. Testing can help identify targeted drugs or trials, but treatment may not work even if a matching biomarker is found.
Approval for the same drug may differ between countries or regions, and each approval has limits on who can receive it. Ask the hospital or doctor to check the current prescribing information against the drug name, regulatory jurisdiction, cancer type, specific biomarker, and previous treatment, then ask whether the hospital actually provides it. A drug’s use in research must also be considered separately from a particular approved use of a marketed drug. For example, China’s National Medical Products Administration granted conditional approval for fulzerasib for adults with advanced non-small cell lung cancer with a KRAS G12C mutation who have received at least one prior systemic therapy. This is an example of a specific indication. It does not mean the drug is appropriate for all KRAS alterations or cancer types, or that the hospital currently has it available.[1][2]
Check all the details in your report
Ask the testing laboratory for the full report, rather than just a screenshot saying that a gene is “positive.” Work with your oncologist or molecular pathology team to identify:
- Disease background: The pathology diagnosis, primary site, subtype, stage, and current disease status.
- Sample: Whether it is tissue or plasma, where and when it was collected, whether it came from the primary tumor or a metastasis, and whether any tissue remains.
- Testing: The laboratory, method, scope, quality, and limitations; whether the study protocol requires a specified test or repeat testing at the study center.
- Findings: The full gene name and specific alteration, fusion partner, or expression score reported. Mutations, amplifications, and fusions are different findings; different alterations within the same gene may also have different meanings.
- Interpretation: Which drug, cancer type, and treatment stage the evidence applies to, and whether it concerns an approved use, evidence from another disease, or something that still needs research. A report’s evidence level is different from a clinical trial’s phase, such as phase I or phase II.
A “variant of uncertain significance” (VUS) means there is currently not enough evidence to determine its meaning. It should not be treated as a valid treatment target simply because the report lists a drug. If findings suggest a possible inherited risk, ask your doctor whether separate germline testing for confirmation and genetic counseling are needed.[1]
What if tissue and plasma results differ?
Tissue and plasma tests use different samples, and their testing coverage may also differ. An older sample reflects the site at the time it was collected; tumors may change over time and with treatment. A negative plasma result does not necessarily rule out the target alteration. Possible reasons include too little tumor DNA in the blood or limits in the test’s coverage.[1][3]
Give both full reports, along with sample collection and treatment dates, to your doctor and the research center. Ask: “Can both methods detect the alteration required by the protocol? Which report does the center accept? Is repeat testing or a new tissue sample needed, and what are the risks and waiting times?” The team should decide whether to collect new tissue based on safety, the material already available, and whether the results could change the decision. Do not send paraffin blocks, slides, or blood samples on your own. First confirm the required materials, paperwork, shipping, and return arrangements with the receiving center and the original pathology department.
After finding a study, confirm the specific site and cohort
You can search by cancer type, specific alteration, and location on the China Drug Clinical Trial Registration and Information Disclosure Platform or ClinicalTrials.gov. These platforms cover different sets of studies. Not finding a study in one search is not enough to conclude that none exists. Record the study name, number, update date, protocol requirements, and hospital. Records on the US platform are submitted by study sponsors or investigators and may lag behind actual conditions. “Not yet recruiting” and “active, not recruiting” do not mean that new patients are being accepted.[4][5]
Some basket trials study one biomarker across several cancer types; umbrella trials assign patients with the same cancer type to different treatment arms based on biomarkers. A platform trial’s overall protocol may remain active even after a particular treatment arm has closed. Write down the following in one line:
Trial number → Hospital and campus → Specific study arm/cohort → Accepted cancer types, specific alterations, and samples → Whether that cohort is currently prescreening and the date of the response.
Contact the research office or investigator through the hospital’s public contact channels and ask: “Is this cohort currently open at your hospital? Do you accept patients from overseas and my report from another hospital? What other tests are needed, are screening slots available, and who will contact me next?” Ask for the investigator’s name, verifiable institutional contact details, and information about ethics review. If you do not receive a clear answer, keep looking for other options. Do not treat a registry page or an intermediary’s claim of a “successful match” as an acceptance notice.
Check other eligibility requirements before sending records
Having the required biomarker is only one step. The research team will also review pathology, stage, previous drugs and their end dates, tumor lesions, physical functioning, organ function, other illnesses, and medications. Some protocols also set requirements for brain metastases, recent treatment, or washout periods. Criteria differ between studies, so do not rule yourself out based on one uncertain requirement.
Prepare a one-page medical summary and have your full pathology and biomarker reports, original imaging files and reports, treatment timeline, recent laboratory results, and medication list ready. First ask the center what it needs and which secure channel to use for sending records. Formal screening may require a pathology review, repeat tests, or new samples. Ask the investigator to explain possible reasons, expected timelines, and risks. Passing prescreening does not mean you are finally enrolled.[1][4]
Before waiting, agree with your current treating doctor on when to reassess your condition and the longest you can safely wait. Clarify who will arrange the next treatment and symptom control if the cohort closes, testing does not meet requirements, or your condition changes. Do not stop medication on your own or adjust treatment yourself to meet a washout period.
Clarify costs, length of stay, and withdrawal before deciding to travel
First request the latest informed consent form in a form you can understand, along with an approximate schedule for screening, treatment, and follow-up tests. Ask whether treatment is assigned randomly, what treatment you might receive, the trial’s possible risks and the possibility of no benefit, and what other options are available if you do not participate. Decide whether to sign only after you understand, and keep the signed documents.
Article 8 of mainland China’s Regulations for the Implementation of the Drug Administration Law states that drug clinical trial sponsors and trial institutions must not charge participants fees related to the clinical trial.[9] For drug trials covered by the Good Clinical Practice for Drug Trials, the 2026 version also requires sponsors to provide trial drugs free of charge and pay for medical tests related to the trial. For trial-related harm, sponsors must cover diagnosis and treatment costs and provide the appropriate compensation or damages.[6] For applicable life sciences and medical research involving humans conducted within China, the ethics review measures prohibit charging participants research-related fees, require appropriate compensation for reasonable expenses incurred through participation, and require prompt, free treatment for research-related harm, with compensation or damages as required by law or agreement.[7]
Ask the research center to explain each of the following in writing: which tests are research-related, what happens if you do not pass screening, routine care and other non-research costs, travel and accommodation costs and compensation for reasonable expenses, treatment for research-related harm, and how to apply for that treatment and compensation. Ask your insurer whether it covers cross-border care, routine care, and complications. Do not assume unconfirmed costs will be reimbursed. If anyone asks you to pay so-called research-related fees, do not pay yet. Ask what the charges are for and verify them with the research institution or ethics review committee.
Ask the research team for approximate dates from screening through the first assessment of treatment response, any requirement to stay near the hospital, whether a local doctor can share follow-up care, and plans for delays. Allow enough flexibility in visas, caregiver arrangements, accommodation, and travel home to cover the actual time needed.
Research participation is voluntary. Applicable ethics rules in China allow participants to withdraw unconditionally at any stage.[7] If you want to withdraw, you can tell the study doctor and ask them to explain safety checks after stopping study treatment, symptom care, choices about the use of records and samples, alternative treatments, and the doctor who will take over your care. Discussing these arrangements helps maintain safe care, but is not a condition of withdrawal. Before enrollment, confirm with the research team whether you can continue receiving the drug after treatment ends or the study is terminated, and who would pay. Do not assume continued access is guaranteed.
Who to contact if symptoms occur
Keep daytime and after-hours phone numbers for your current care team and study doctor, the hospital address, and the trial number. Carry a medication list and study contact card. Report new or worsening symptoms promptly, even if you are unsure whether they are related to the study.
Fever or chills during cancer treatment may signal an infection. Contact your care team as soon as possible and seek care according to their emergency plan. If you cannot reach them or your condition is serious, go to the nearest emergency department. Ask your doctor in advance what fever threshold should prompt action in your situation and whom to contact. While waiting for screening, also contact your current care team; do not simply wait for a routine callback from the research team.[10]
For severe difficulty breathing, chest pain, sudden confusion or loss of consciousness, or heavy bleeding in mainland China, call 120 immediately or go to the nearest emergency department. Do not wait for the research team to call back. Tell emergency staff about the trial you are participating in, your most recent dose, and your other medications. Family members should contact the research team after emergency care has been arranged. The research team should explain follow-up care and the procedures for reporting research-related harm and covering its costs.[6][8]
Frequently asked questions
I have already had a large gene panel. Do I need more testing?
Possibly. Ask the center whether your existing test covers the required types of alterations, whether the sample meets the protocol requirements, whether review by the center is mandatory, and how long new testing would take and who would pay.
Does a negative plasma result mean there is no treatment target?
Not necessarily. Tests have limits in coverage and sensitivity. Ask your doctor to consider the sample, testing method, and your condition when deciding whether tissue testing is still needed and can be done safely.[1][3]
Why will a study not accept me if I have the same gene finding?
The protocol may require a specific mutation, fusion, expression threshold, cancer type, or previous treatment. The study arm may also not currently be open at that hospital. Ask the research team to identify the specific requirements you do not meet or that still need checking.
Do I have to wait until all standard treatments have failed before joining?
Not necessarily. Different trials study different stages of treatment. Ask your doctor to check the protocol against your current point in treatment. Do not wait or change treatment on your own.[4]
Can I refuse if the research center says I need a new biopsy?
You can decide whether to have it. Ask the investigator to explain the biopsy’s purpose, risks, and how refusing would affect screening. If you decline or a sample cannot be collected safely, also discuss other options with your treating doctor.[7]
What if I do not pass screening or the cohort is full?
Ask the center to explain why, whether you can provide additional records, and whether another suitable study is available. Share the outcome with your current treating doctor and continue care as agreed in advance. Do not stop medication on your own while waiting for a place.
Am I guaranteed continued access to the study drug after the trial ends?
No. Before enrollment, ask the research team to explain the conditions for drug supply, costs, follow-up, and referral after completion or withdrawal, and arrange a doctor to take over your care.
What if my report suggests an inherited risk in my family?
A finding in a tumor sample does not establish that it is inherited. Ask your doctor whether separate germline testing and genetic counseling are needed, then discuss what the finding may mean for your family.[1]
Sources
The following materials were checked on November 6, 2026. Study protocols, indications, and recruitment status can change. Verify them with the responsible institution.
-
US National Cancer Institute: Biomarker Testing for Cancer Treatment
-
US FDA: Information on Negative Plasma Results in the Historical Approval Record for Resolution ctDx FIRST (the device was withdrawn in 2025; this is only a historical example for a specific product and population)
-
Good Clinical Practice for Drug Trials (2026 Revision), especially Articles 2, 27, and 45; notice of entry into force
-
National Health Commission: Measures for the Ethical Review of Life Sciences and Medical Research Involving Humans, Articles 2 and 17
-
Regulations for the Implementation of the Drug Administration Law of the People’s Republic of China, Article 8, effective May 15, 2026.
-
US National Cancer Institute: Infection and Neutropenia During Cancer Treatment